From the Guidelines
For a complicated urinary tract infection (UTI) requiring Zosyn (piperacillin-tazobactam), I recommend intravenous Zosyn at a dose of 3.375g every 6 hours or 4.5g every 8 hours for 7 days, as short-duration therapy has been shown to be as effective as long-duration therapy in achieving clinical success 1.
Key Considerations
- Dosage should be adjusted for patients with renal impairment, as indicated in the guidelines for complicated intra-abdominal infection 2.
- Zosyn is appropriate for complicated UTIs caused by resistant organisms or in patients with risk factors like recent hospitalization, immunosuppression, or recent antibiotic use.
- Once culture results are available, therapy should be narrowed to the most appropriate antibiotic to minimize the risk of antibiotic resistance and side effects.
Monitoring and Treatment
- Patients should be monitored for clinical improvement within 48-72 hours, including resolution of fever, decreased pain, and improved urinalysis results.
- Common side effects of Zosyn include diarrhea, headache, and nausea, and patients should be advised to report any adverse effects promptly.
- After IV therapy, patients may be transitioned to oral antibiotics based on culture sensitivities to complete the treatment course, as determined by the treating physician.
Evidence-Based Decision
The recommendation for a 7-day treatment course is based on the most recent and highest-quality study available, which found that short-duration therapy (5-7 days) results in similar clinical success as long-duration therapy (10-14 days) for complicated UTIs, including those with bacteraemia 1. This study provides strong evidence for the effectiveness of short-duration therapy in achieving clinical success, while minimizing the risk of antibiotic resistance and side effects.
From the FDA Drug Label
The FDA drug label does not answer the question.
From the Research
Treatment Options for Complicated UTI
- The treatment of complicated urinary tract infections (cUTIs) depends on various factors, including the causative organism, local susceptibility patterns, and patient-specific factors 3.
- For cUTIs caused by ESBL-producing Enterobacteriaceae, treatment options include piperacillin-tazobactam, carbapenems, and aminoglycosides 3, 4.
- Piperacillin-tazobactam is a broad-spectrum antibiotic that has been shown to be effective in treating various infections, including cUTIs 5.
- Aminoglycosides have been found to be non-inferior to carbapenems and piperacillin-tazobactam in treating bloodstream infections of urinary source caused by ESBL-producing Enterobacteriaceae 4.
Duration of Therapy
- The optimal duration of therapy for hospitalized patients with cUTIs is not well established, but studies suggest that 7-10 days of treatment may be sufficient for some patients 6.
- However, the duration of therapy may need to be individualized based on the patient's response to treatment and the presence of any underlying conditions 6.
Zosyn (Piperacillin-Tazobactam) for Complicated UTI
- Zosyn is a combination antibiotic that contains piperacillin and tazobactam, and it has been shown to be effective in treating cUTIs caused by various organisms, including ESBL-producing Enterobacteriaceae 3, 5.
- The use of Zosyn for cUTIs is supported by studies that have demonstrated its efficacy and safety in treating these infections 5.